HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)

HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $80.00 target price on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd. Guggenheim lifted their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a buy rating in a report on Tuesday, February 27th. Finally, TD Cowen began coverage on shares of Celldex Therapeutics in a report on Wednesday, December 20th. They issued an outperform rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Celldex Therapeutics has a consensus rating of Moderate Buy and a consensus target price of $66.00.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $37.98 on Wednesday. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -13.05 and a beta of 1.49. Celldex Therapeutics has a one year low of $22.11 and a one year high of $53.18. The company’s fifty day moving average price is $42.03 and its 200-day moving average price is $35.80.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.19. The firm had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. Equities research analysts expect that Celldex Therapeutics will post -2.85 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently made changes to their positions in the business. Wellington Management Group LLP increased its holdings in shares of Celldex Therapeutics by 19.2% in the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after buying an additional 1,044,728 shares during the last quarter. Eventide Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after buying an additional 2,030,013 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Celldex Therapeutics by 0.8% in the 1st quarter. BlackRock Inc. now owns 3,250,638 shares of the biopharmaceutical company’s stock worth $116,958,000 after buying an additional 25,922 shares during the last quarter. State Street Corp increased its holdings in shares of Celldex Therapeutics by 20.4% in the 2nd quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock worth $87,050,000 after buying an additional 546,124 shares during the last quarter. Finally, Kynam Capital Management LP increased its holdings in shares of Celldex Therapeutics by 23.1% in the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock worth $88,064,000 after buying an additional 600,000 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.